Beyond Generics: How Policy and Investment are Positioning India as a Drug Discovery Hub

India Pharma Poised to Lead Global Biologics Boom as Government Unveils Mega Initiatives​

New Delhi, Apr 13 India is strategically positioned to assume a leading role in the rapidly evolving global pharmaceutical landscape. With the industry shifting focus towards biologics, biosimilars, and specialty medicine, the government has reiterated a deep commitment to support value-based, high-tech growth.

Union Minister J P Nadda, Minister of Chemicals & Fertilisers and Health & Family Welfare, emphasized this structural change during the India Pharma 2026 event. He noted that while India has historically gained global recognition as the 'pharmacy of the world' for its affordable generics, the market dynamics are undergoing a major transformation.

In this new environment, Nadda asserted that India is not only capable of adopting these advanced models but is also uniquely placed to spearhead them globally. The government plans to create a robust policy framework that actively supports innovation and strengthens research capabilities across the sector.

Pivoting from Generics to High-Value Biologics​

Acknowledging the changing global emphasis, Minister of State Anupriya Patel highlighted the need for Indian drugmakers to pivot their focus. She stated that the traditional "generics model" is facing global strain, necessitating increased investment in biosimilars, biologics, and innovative drugs.

To facilitate this strategic shift, the government has launched significant industrial initiatives. The administration has also placed a strong focus on strengthening domestic manufacturing self-reliance. This effort is being driven through schemes like the Production Link Incentive (PLI) and the development of dedicated bulk drug parks.

Minister Nadda previously highlighted the introduction of Biopharma SHAKTI, an initiative with an outlay of ₹10,000 crore over five years. This major investment underlines the administration's goal of making the Indian pharmaceutical industry a global hub for high-value drug creation.

Modernizing the Regulatory Ecosystem for Innovation​

To match the global push toward advanced medicine, significant structural reforms are underway within the regulatory bodies. Anupriya Patel confirmed the restructuring of the Central Drugs Standard Control Organisation (CDSCO).

This modernization includes the creation of a new scientific review workforce, which will hire more than 1,500 professionals who are subject matter experts. Furthermore, the development of a comprehensive network of 1,000 clinical trial sites will be established to bolster research infrastructure.

Recognizing the transformative power of technology, the government is also placing special emphasis on integrating artificial intelligence (AI) into drug discovery and development processes.

Fostering Global Drug Discovery Hub Status​

These comprehensive steps signal a major overhaul aimed at enhancing India's status on the world stage. The concerted efforts in policy formulation, investment, and regulatory modernization are expected to position India as a preferred destination.

The proactive measures aim to facilitate a seamless transition, enabling India to transition toward high-value innovation. By promoting deeper industry participation and effective public-private partnerships, the nation is building resilient supply chains and securing its future as a global pharmaceutical leader.